Proactive Investors - Run By Investors For Investors

Cronos Group partners with foundation for cannabinoid-based skin care treatments

Research will look into potential applications of cannabinoids to regulate skin health and treat skin disorders
Cannabis products.
Cronos Group is an integrated cannabis company.

Cronos Group Inc (NASDAQ:CRON) (TSX: CRON) said on Monday it has entered into a sponsored research agreement to explore the use of cannabinoids and their role in regulating skin health and skin disorders. 

The agreement was reached with Technion Research and Development Foundation, which is a subsidiary of the Technion - Israel Institute of Technology. The preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions: acne, psoriasis and skin repair.

"We believe that the potential applications of cannabinoids to regulate skin health and treat skin disorders are vast, and we are excited to begin exploring these applications through our partnership with Technion," said Mike Gorenstein, the Cronos Group CEO.

READ: Cronos Group partners with Aleafia Health to work on medical cannabis study to treat insomnia

The endocannabinoid system and the cannabinoids that modulate its activity are believed to have an important role in regulating skin health and skin disorders.

The research will be led by Technion faculty members Dr David Meiri and Dr Yaron Fuchs, two of the world's leading researchers in cannabis and skin stem cell research. 

The research will utilize Dr Meiri's cannabis strain database of over 80 cultivars and Cronos Group's strain specific cannabis oils to isolate and investigate the effects of individual and combinations of cannabinoids, potentially including rare cannabinoids, for treating acne, psoriasis and wounds using stem cell-derived organoid cultures developed by Dr Fuchs' laboratory and mouse models. 

Cronos Group expects to be able to adapt the individual and combinations of cannabinoids to develop products for each of these three applications and expects to receive an exclusive, worldwide license to market and manufacture such products.

Shares of Cronos Group rose 3.85% to $10.24.

Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across five continents. The company is based in Toronto.

Reporting by Rene Pastor, contactable on [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CRON profile View Profile

Cronos Group Inc Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use